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Objective. The aim of this study was to evaluate the predictive value of pretreatment serum hemoglobin level (Hb) together with a series
of clinical and pathological variables available before neoadjuvant chemotherapy in locally advanced squamous cervical cancer.
Methods. The influence on response to neoadjuvant chemotherapy of a series of pretreatment clinico-pathological features: hemoglobin
level at diagnosis, age, parity, menopausal status, body mass index, clinical stage, tumor diameter, and nuclear grading were analyzed on 73
patients with locally advanced cervical cancer treated with platinum-based neoadjuvant chemotherapy followed by radical surgery. The
relationships between pretreatment variables and response to chemotherapy were assessed in univariate and multivariate settings. A
univariate and multivariate logistic regression model was adapted to predict an ‘‘optimal’’ response (pathological complete response or more
than 50% reduction in tumoral diameter) or ‘‘sub-optimal’’ response (<50% reduction in tumoral diameter).
Results. Seventy-three patients—clinical stage: Ib2: 29 (39.7%) IIa: 22 (30.1%) IIb: 22 (30.1%)—received 3 cycles of platinum-based
neoadjuvant chemotherapy followed by type III radical hysterectomy. A complete response to neoadjuvant chemotherapy was significantly
associated with higher level of pretreatment hemoglobin (mean 14.0 mg/dl) compared to patients with 50% response (12.7 mg/dl) or <50%
(11.9 mg/dl) (P = 0.002). At multivariate analysis, Hb level was found to be the most powerful and significantly related factor to response to
neoadjuvant chemotherapy. A hemoglobin threshold of 12 mg/dl was able to distinguish between patients—with 12 mg/dl—at higher
probability to respond to neoadjuvant chemotherapy from the ones at lower probability (hemoglobin level under 12 mg/dl). Patients with a
complete response to chemotherapy had a 100% survival compared to 93.1% and 53.8% for patients with responses 50% and <50%
respectively (P = 0.0001). Patients with a pretreatment hemoglobin level of 12 mg/dl showed a survival of 87% compared to 63% for
patients with a lower hemoglobin level (P = 0.008).
Conclusions. Pretreatment Hb level showed a prognostic and independent predictive value for response to neoadjuvant chemotherapy in
locally advanced cervical cancer. In our preliminary report, performed on a limited sample, a threshold of 12 mg/dl seems to be helpful to
distinguish between ‘‘optimal’’ and ‘‘non-optimal’’ response.
D 2005 Elsevier Inc. All rights reserved.Keywords: Hemoglobin; Response to chemotherapy; Locally advanced squamous cervical cancer0090-8258/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2005.07.079
* Corresponding author.
E-mail address: casazola@libero.it (P. Zola).Introduction
Cervical cancer is the third most common gynecological
malignancy in the developed world. Locally advanced
disease often shows a 5-year overall survival of <70% [1].
Multimodal treatment strategies, including concomitant9 (2005) S187 – S191
Table 1
Univariate analysis for response to chemotherapy
Clinical parameter CR 50% <50% P value
Age (mean) 47.7 52.1 47.4 0.30a
Parity (mean
(mean rank))
3.0 (46.4) 2.1 (36.2) 1.8 (31.4) 0.05b
Menopausal
status (%)
29.4 44.1 26.5 0.30c
BMI (mean) 25.5 24.4 24.6 0.57a
Stage (%) 0.86c
Ib2 9 (31.0) 10 (34.5) 10 (34.5)
IIa 5 (22.7) 9 (40.9) 8 (36.4)
IIb 4 (22.2) 10 (34.5) 9 (30.8)
Grading (%) 0.27c
1 – 1 (3.4) –
2 7 (38.9) 7 (24.1) 13 (50.0)
3 11 (61.1) 21 (72.4) 13 (50.0)
Tumor
diameter—cm
(mean)
56.6 52.9 53.4 0.57a
Hb pretreatment
level—mg/dl
(mean)
13.8 12.7 11.9 0.002a
CR: complete response; 50%: reduction of tumoral diameter of 50% or
more after NACT; <50%: reduction of tumoral diameter of <50% after
NACT. Underscored: statistical significant at 0.05 level (2-sided).
a F test (ANOVA).
b U test (Kruskal–Wallis test).
c Pearson’s Chi-square test.
Table 2
Univariate logistic analysis for ‘‘non-optimal’’ response to chemotherapy
(<50% reduction)
Clinical pretreatment parameter HR CI 95%a P value
Age 0.98 0.94–1.05 0.21
Parity 0.71 0.48–1.05 0.09
Menop status 2.14 0.79–5.77 0.13
BMI 0.98 0.85–1.12 0.78
Stage 0.98
Ib2 1
IIa 1.08 0.34–3.45
IIb 1.08 0.34–3.45
Grading (%) 0.25
1 1
2 0.05 0.00–2.85
3 2.28 0.84–6.16
Tumor diameter (cm) 0.99 0.95–1.03 0.76
Hb pretreatment level mg/dl (continuous) 0.66 0.49–0.90 0.008
Hb  12 mg/dl 1
Hb < 12 mg/dl 6.83 2.16–21.60 0.001
HR: hazard ratio.
a CI: 95% confidence interval.
L. Fuso et al. / Gynecologic Oncology 99 (2005) S187–S191S188cisplatin-based chemotherapy and radiotherapy or neoadju-
vant chemotherapy followed by radical surgery or by a
combination of concurrent chemoradiation and surgery had
been claimed to improve survival and local control rates [2].
Neoadjuvant chemotherapy (NACT) followed by radical
surgery (RS) has received increasing attention, being
demonstrated to be feasible, and the outcome has been
improved. In particular, the operability rate rose from 48% to
100% after NACT with no influence on surgery-related
morbidity. The observed 5-year survival rate in patients
treated with NACT followed by surgery was higher than in an
exclusive radiation therapy group by 65% versus 46% [3–5].
Some efforts have sought to predict chemotherapy resistance
by assessing biochemical factors related to tumor cell biology
and tumor aggressiveness [6–8]. The respective merits of
these treatments will be clarified when the results of new
ongoing randomized controlled trials will be available.
Anemia is the most frequently observed hematological
abnormality factor among cancer patients; however, its im-
pact on tumor biology is not well understood. Several recent
retrospective clinical studies showed that anemia is not only a
negative prognostic factor, impairing disease-free and overall
survival, but also a negative predictive parameter in radio-
therapy-treated patients with solid tumors, including carcino-
ma of the cervix [9]. Many reports have documented a cor-
relation between Hb levels before and during treatment and
the response to chemotherapy [10], suggesting low Hb level
as a negative predictive parameter in chemotherapy-treated
patients affected by several solid tumors. It is postulated that
lower Hb levels resulting in decreased oxygen carryingcapacity may lead to increased tumor hypoxia, chemotherapy
resistance, and increased tumor angiogenesis [11].
The aim of this report is to investigate whether a
relationship exists between pretreatment Hb levels and
response to neoadjuvant chemotherapy in patients treated
with NACT and radical surgery. Other pretreatment clinical
variables, possibly predictive of chemotherapy response, are
investigated.Methods
Seventy-three patients with locally advanced cervical
cancer, staged Ib2–IIb, underwent neoadjuvant chemo-
therapy followed by radical surgery at the Gynecology
Oncology department of the University of Turin between
1997 and 2004 (see Table 1). Data were collected in a
database and entered with the following fields: FIGO stage
Ib2–IIb disease, histologically confirmed squamous cervi-
cal cancer, no previous radiation, treatment with neo-
adjuvant chemotherapy followed by radical surgery (type
III radical hysterectomy and pelvic and paraortic lympha-
denectomy), availability of the following pretreatment
variables: hemoglobin level at diagnosis, age, parity,
menopausal status, body mass index, clinical FIGO stage,
tumor diameter, nuclear grading on tumor biopsies, response
to chemotherapy according to RECIST criteria for solid
tumors, and follow-up data. The response to chemotherapy
was reclassified as complete response (disappearance of all
microscopic neoplastic foci with negative lymph nodes),
tumor load reduction of more than 50% (reduction of the
maximum tumoral diameter of more than 50% compared to
the initial measurement), tumor load reduction of <50%
(reduction of the maximum tumoral diameter of <50%
compared to the initial measurement). Patients were all
Table 3
Multivariate logistic analysis for ‘‘non-optimal’’ response to chemotherapy
Variables in
the equation
HR CI 95%a Wald 2 log
likelihood
P value
Hb pretreatment
level mg/dl
(continuous)
0.66 0.49–0.90 6.88 87.2 0.008
Hb  12 mg/dl 1 10.70 83.3
Hb < 12 mg/dl 6.83 2.16–21.60 0.001
HR: hazard ratio.
a CI: 95% confidence interval.
L. Fuso et al. / Gynecologic Oncology 99 (2005) S187–S191 S189treated with a platinum-based chemotherapy giving at least a
dose intensity of 20 mg/m2/weekly for 3 courses every 21
days. The study protocol had been reviewed by the ethics
committee, and written informed consent was obtained from
each patient. The relationships between the pretreatment
variables and response to chemotherapy were assessed in a
univariate setting by means of analysis of variance
(ANOVA) for continuous variables and Mann–Whitney
non-parametric test to evaluate whether two independent
samples are from the same population. A univariate and
multivariate logistic regression model is adapted to predict
an optimal response (complete or more than 50% reduction)
or a suboptimal response (<50% reduction) based on values
of a set of pretreatment predictor variables. The Kaplan–Fig. 1. Survival curves and analysis for this patient gMeier model, based on estimating conditional probabilities
at each time point when an event occurs, is used to estimate
the survival rate of patients with a good and poor response
to chemotherapy. Actuarial survival curves are generated,
and the log rank test is adapted for comparing the equality of
survival distributions. Calculations were executed with the
SPSS statistical package version 12 (SPSS Inc, IL, USA).Results
Seventy-three patients received neoadjuvant chemother-
apy. The distribution of clinical stage was as follows: stage
Ib2: 29 (39.7%), IIa: 22 (30.1%), IIb: 22 (30.1%). Overall
mean age was 49.3 years, and median parity number was 2.
Thirty-four patients (46.6%) were menopausal when enter-
ing the study. The mean body mass index (BMI) was 24.3
kg/m2. The grade of differentiation at diagnostic biopsies
was as follows: G1 = 1 patient (1.4%), G2 = 27 patients
(37.0%), G3 = 45 patients (61.6%). Tumor diameter at
diagnostic procedure had an overall median value of 50 cm;
17 patients (23.3%) had a neoplasm less than 5 cm and 56
patients 5 cm (76.7%). The response to chemotherapy was
complete in 18 (24.7%) patients, 50% in 29 (39.7%), and
<50% in 26 (35.6%) patients.roup to stratified by response to chemotherapy.
L. Fuso et al. / Gynecologic Oncology 99 (2005) S187–S191S190Table 1 shows a univariate analysis for response to
chemotherapy in which the distribution of each predictive
factor is observed across the three levels of response:
complete, 50%, <50%. Patients who demonstrated a
complete response had a significantly higher level of
pretreatment hemoglobin (13.8 mg/dl) compared to patients
with a 50% response (12.7 mg/dl) or <50% (11.9 mg/dl;
P = 0.002). A trend towards a better response is also noticed
for patients with a higher parity (P = 0.05). Table 2 reports a
logistic model created to derive the hazard ratio for a non-
optimal response, considered when a <50% reduction in
tumor measurement was encountered. The dichotomous
dependent variable had the following distribution: 64.4%
(47/73 patients) showed complete response or 50%, 35.6%
showed <50% response (26/73 patients). For each explan-
atory pretreatment variable, the hazard ratio of <50%
response and 95% confidence interval are displayed. At
multivariate analysis (Table 3), Hb level is the most
powerful and significantly related factor to response to
chemotherapy. A patient with an Hb level increment of 1
mg/dl had her risk of not responding to platinum-based
chemotherapy decreased at 0.6. On the other hand, a
hemoglobin threshold of 12 mg/dl allowed a distinction
between two groups where the one with a pretreatment
hemoglobin level of 12 mg/dl has a probability to respond
to neoadjuvant chemotherapy of nearly seven times higher.Fig. 2. Survival curves and analysis for this patFig. 1 shows the Kaplan–Meier actuarial survival curves by
response to chemotherapy. Patients with a complete
response to chemotherapy had a 100% survival rate
compared to 93.1% for 50% responders and 53.8% for
<50% responders (P = 0.0001). Fig. 2 shows the Kaplan–
Meier actuarial survival curves for hemoglobin threshold of
12 mg/dl. Patients with a pretreatment hemoglobin level of
12 mg/dl showed a survival rate of 87% compared to 63%
of patients with a lower hemoglobin level (P = 0.008).Discussion
Neoadjuvant chemotherapy followed by radical surgery
emerged as an alternative treatment to conventional radio-
therapy (external beam therapy and brachytherapy) and
more recently chemoradiotherapy for locally advanced
cervical cancer. Awaiting results from ongoing trials, some
efforts were made to predict in advance the response to
chemotherapy of a subgroup of patients sensitive to the
existing drugs to improve survival. There is increasing
evidence that the response to chemotherapy is a good, or
perhaps the most powerful, prognostic factor in locally
advanced cervical cancer. In our report, patients who had a
complete response to chemotherapy demonstrated a survival
of 100% compared to 93.1% and 53.5% for reductionient group stratified by hemoglobin level.
L. Fuso et al. / Gynecologic Oncology 99 (2005) S187–S191 S191of the tumor of 50% and <50%, respectively (log rank:
P value = 0.0001). Lacking reliable clinical predictive
factors, some authors tested chemotherapy resistance by
assessing biochemical factors such as serum levels of
squamous cell carcinoma antigen [12], microvessel density
[6,7], oncogenes and tumor suppressor genes [13], and
cyclooxygenase-2 [8]. Anemia is the most frequently
observed hematological abnormality factor among cancer
patients. Its impact on tumor biology is not well under-
stood yet [10,14]. Suppression of erythroid progenitor
cells by tumor cytokines (IL-6), changes in iron metab-
olism, alteration of erythropoietin response, or simply
chronic hemorrhage are some of the mechanisms that
have been associated with pretreatment tumor-associated
anemia [15].
In the present study, we tested clinical pretreatment
parameters and serum hemoglobin level to predict chemo-
therapy resistance. Neoadjuvant chemotherapy response
was significantly more likely in patients with high pretreat-
ment Hb values; the threshold of 12 mg/dl is shown to be a
good cut-off between ‘‘optimal’’ response (complete and
50% response) and ‘‘non-optimal’’ response (<50%
reduction in tumor diameter). It has been reported repeat-
edly that anemia is associated with both decreased local
control and overall survival in large numbers of patients
affected by cervical cancer that are treated with radiotherapy
[16–19]. One hypothesis is that hypoxic cell fraction of the
tumor increases as a consequence of anemia and confers to
these cellular clones a lowered degree of radiosensitivity
[20]. Currently, there are few data available on the
correlation between Hb pretreatment levels and response
to neoadjuvant chemotherapy. In our report, we demon-
strated a relationship between high levels of pretreatment
serum hemoglobin and good response to neoadjuvant
chemotherapy. Our preliminary data have to be confirmed
by wider studies. Recombinant human erythropoietin (rh-
EPO) or blood transfusion can be used to increase blood Hb
levels before chemotherapy and perhaps during the treat-
ment with the aim of improving tumor oxygenation and
convert cells to chemosensitivity. On the contrary, it may be
supposed that hemoglobin levels may be useful to identify
the more aggressive tumors which, because of chemo-
resistance, should not be treated with neoadjuvant chemo-
therapy followed by radical surgery.Conclusions
Pretreatment serum hemoglobin level was found to be
predictive of the response to chemotherapy, and a threshold
of 12 mg/dl could be helpful to distinguish between
‘‘optimal’’ and poor response. If these results could be
confirmed on a wider sample, clinical trials will need to be
performed to determine whether to increase hemoglobin
levels lead to improved local control rates and survival.References
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